PO.BCS01.06 · 生物信息与计算

利用mRNA衍生标签从H&E全切片图像中无偏地AI检测三级淋巴结构可预测NSCLC生存

Unbiased AI detection of tertiary lymphoid structures from H&E whole-slide images using mRNA-derived labels predicts survival in NSCLC

海报缩略图:利用mRNA衍生标签从H&E全切片图像中无偏地AI检测三级淋巴结构可预测NSCLC生存
编号 72 展板 3 时间 4/19 02:00–05:00 区域 Section 4 主讲 Jessica Kim, BS
分会场 Digital Pathology 1
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Anthony J. Wong1, Jessica Kim2, Shinkyo Yoon3, Young Kwang Chae1

1Northwestern Univ. Feinberg School of Medicine, Chicago, IL,2Northwestern University, Evanston, IL,3Department of Oncology, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, Korea, Republic of

摘要 Abstract

中文摘要
三级淋巴结构(TLS)是公认的非小细胞肺癌(NSCLC)预后标志物,然而从H&E全切片图像(WSI)中进行人工检测仍具主观性且耗费人力,限制了其临床应用。 我们开展了一项整合转录组学与组织病理学方法的分析。使用xCell对TCGA NSCLC mRNA表达数据(n=922)进行分析,计算B细胞、T细胞(CD4+和CD8+)和树突状细胞的富集评分。TLS富集评分通过对B细胞、T细胞和树突状细胞的z标准化xCell聚合富集评分取平均值计算得出。位于上四分位的样本标记为“TLS富集”,位于下四分位的样本标记为“TLS非富集”。随后使用这些由四分位衍生的标签,采用Imagene的OI Suite平台,以3:1的训练-测试比例,训练用于从TCGA H&E全切片图像检测TLS的机器学习模型。采用单变量和多变量Cox比例风险回归分析评估AI预测的TLS富集是否独立预测总生存期(OS)。 AI模型在TLS检测中表现稳健,训练集AUC达0.84,测试AUC达0.92。Kaplan-Meier分析显示,AI预测的TLS富集组患者(n=366,366/922=39.7%)相较于AI预测的TLS非富集组(n=556,556/922=60.3%)OS得到改善(HR 0.76;95% CI 0.61-0.94;log-rank p=0.014)。在校正年龄、性别和组织学类型后,AI预测的TLS富集仍与更佳的OS独立相关(HR 0.77;95% CI 0.61-0.97;p=0.025)。在各协变量中,较高年龄(高于队列中位数)与更差的生存相关(HR 1.25;95% CI 1.01-1.55;p=0.039),而性别和组织学亚型(LUSC vs LUAD)不是显著预测因子(分别为HR 1.12;95% CI 0.89-1.41;p=0.337和HR 0.99;95% CI 0.79-1.25;p=0.957)。这些发现表明,模型的TLS富集预测捕获了具有临床意义的肿瘤微环境特征,能够在标准临床病理因素之外对OS进行分层。 AI辅助的H&E WSI分析有助于将TLS富集识别为NSCLC总生存期的潜在独立预测因子。这种无偏的计算方法为在资源有限的环境中仅使用H&E WSI进行TLS评估和生存预测提供了可重复且客观的方法,并可能在精准免疫治疗背景下支持下游治疗选择。
查看英文原文 English abstract
Tertiary lymphoid structures (TLS) are recognized prognostic markers in non-small cell lung cancer (NSCLC), yet manual detection from H&E whole-slide images (WSI) remains subjective and labor-intensive, limiting clinical adoption. We conducted an integrative analysis combining transcriptomic and histopathologic approaches. TCGA NSCLC mRNA expression data (n = 922) were analyzed using xCell to compute enrichment scores for B cells, T cells (CD4+ and CD8+), and dendritic cells. TLS enrichment score was calculated by averaging z-standardized xCell aggregate enrichment scores for B cells, T cells, and dendritic cells. Samples in the upper quartile were labeled ‘TLS enriched' and those in the lower quartile were labeled ‘TLS non-enriched.' These quartile-derived labels were then used to train a machine learning model for TLS detection from TCGA H&E whole-slide images using Imagene's OI Suite platform with a 3:1 train-test split. Univariable and multivariable cox proportional hazards regression analysis evaluated whether AI-predicted TLS enrichment independently predicted overall survival (OS). The AI model demonstrated robust performance for TLS detection, achieving an AUC of 0.84 in the training set and a test AUC of 0.92. Kaplan-Meier analysis showed that patients in the AI-predicted TLS-enriched group (n = 366, 366/922=39.7%) demonstrated improved OS compared with the AI-predicted TLS-non-enriched group (n = 556, 556/922=60.3%; HR 0.76; 95% CI 0.61-0.94; log-rank p = 0.014). Adjusting for age, sex, and histology, AI-predicted TLS enrichment remained independently associated with favorable OS (HR 0.77; 95% CI, 0.61-0.97; p = 0.025). Among the covariates, older age (greater than the cohort median) was associated with worse survival (HR 1.25; 95% CI, 1.01-1.55; p = 0.039), while sex and histologic subtype (LUSC vs LUAD) were not significant predictors (HR 1.12; 95% CI, 0.89-1.41; p = 0.337 and HR 0.99; 95% CI, 0.79-1.25; p = 0.957, respectively). These findings indicate that the model's TLS-enrichment prediction captures clinically meaningful tumor microenvironment features that stratify OS beyond standard clinicopathologic factors. AI-assisted H&E WSI analysis helps identify TLS enrichment as a potential independent predictor of overall survival in NSCLC. This unbiased computational approach provides a reproducible and objective methodology for TLS assessment and survival prediction in a resource-limited context using H&E WSI only, and may support downstream treatment selection in the context of precision immunotherapy.
利益披露 Disclosure
A. J. Wong, None.. J. Kim, None.. S. Yoon, None. Y. Chae, AbbVie ). Bristol Myers Squibb Independent Contractor, ). Biodesix Independent Contractor, ). Freenome ). Predicine ). Tempus Independent Contractor, ). Imagene AI ). Picture Health Independent Contractor, ). Oncohost Independent Contractor, ). Regeneron Independent Contractor, ). Roche/Genentech Independent Contractor. AstraZeneca Independent Contractor. Foundation Medicine Independent Contractor. Neogenomics Independent Contractor. Boehringher Ingelheim Independent Contractor. ImmuneOncia Independent Contractor. Lilly Oncology Independent Contractor. Merck Independent Contractor. Takeda Independent Contractor. Lunit Independent Contractor.

← 返回 AACR 2026 检索